Safety and Efficacy of Switching Injected Peptide Long-Acting Somatostatin Receptor Ligands to Once Daily Oral Paltusotine: ACROBAT Edge Phase 2 Study

Ítems similars

• OR23-05 Human Absorption, Metabolism, Excretion, and Absolute Oral Bioavailability of (14)C-CRN00808, an Orally Bioavailable, Nonpeptide, Selective, Somatostatin Receptor 2 (sST2) Biased Agonist for the Treatment of Acromegaly
  per: Madan, Ajay, et al.
  Publicat: (2020)
• SAT-429 Final Results from the First in Man Phase 1 Clinical Trial of CRN00808, an Orally Bioavailable sst2-Selective, Nonpeptide Somatostatin Biased Agonist, for the Treatment of Acromegaly: Safety, Pharmacokinetics, Pharmacodynamics, and Midazolam Drug Interaction in Healthy Volunteers
  per: Madan, Ajay, et al.
  Publicat: (2019)
• SAT-433 Long-Acting Pasireotide Provides Clinical Benefit to Patients with Uncontrolled Acromegaly over Continued Treatment with First‑Generation Somatostatin Analogues (SSAs): Results from Phase 3b, Open-Label Study
  per: Gadelha, Mônica, et al.
  Publicat: (2019)
• Somatostatin, as a Bridge Between the GH-Axis and the Gth-Axis
  per: Mizrahi, Naama, et al.
  Publicat: (2021)
• Olfactory Neuroblastoma: The Adjunctive Role of Somatostatin Agonists After Surgery
  per: Toral, Fernando Pazos, et al.
  Publicat: (2021)